CYSLTR1
Cysteinyl leukotriene receptor 1
As of the edition of 20 October 2026, CYSLTR1 (cysteinyl leukotriene receptor 1, UniProt Q9Y271) has 3 drugs tested at it and 5 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9Y271
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 2
- Disease areas
- Lungs and airways; Immune system; Ear, nose and throat; Infections; Urinary and reproductive; Cancer; Pregnancy and women's health; Heart and blood vessels
- Registered trials of its drugs
- 212
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 3 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Montelukast | Marketed | Phase 4 | none listed |
| Zafirlukast | Marketed | Phase 2 | none listed |
| Pranlukast | Marketed | Phase 3 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Undetermined | 3 |
| Total on the list | 5 |
| Company | Route |
|---|---|
| Organon | Route B |
| Ono Pharmaceutical | Route B |
The other 3 companies at CYSLTR1
In the product5 companies in all; 3 are not named here, and no score is.
See the 5 companies at CYSLTR1, ranked, with the facts behind eachRequest access. Nothing is shown until you do.